A detailed history of Oppenheimer & CO Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 87,569 shares of BMEA stock, worth $351,151. This represents 0.01% of its overall portfolio holdings.

Number of Shares
87,569
Previous 91,522 4.32%
Holding current value
$351,151
Previous $411,000 115.09%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$4.23 - $10.1 $16,721 - $39,925
-3,953 Reduced 4.32%
87,569 $884,000
Q2 2024

Aug 07, 2024

BUY
$4.14 - $15.3 $322,166 - $1.19 Million
77,818 Added 567.85%
91,522 $411,000
Q1 2024

May 06, 2024

SELL
$13.92 - $19.5 $162,279 - $227,331
-11,658 Reduced 45.97%
13,704 $204,000
Q4 2023

Feb 13, 2024

BUY
$8.37 - $19.8 $212,279 - $502,167
25,362 New
25,362 $368,000
Q2 2023

Aug 02, 2023

BUY
$21.66 - $41.8 $260,873 - $503,439
12,044 New
12,044 $264,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $117M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.